Sarepta Therapeutics Dirección

Dirección controles de criterios 4/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Doug Ingram

Chief Executive Officer (CEO)

US$1.7m

Compensación total

Porcentaje del salario del CEO	48.1%
Permanencia del CEO	7yrs
Participación del CEO	0.4%
Permanencia media de la dirección	3.5yrs
Promedio de permanencia en la Junta Directiva	8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Doug Ingram en comparación con los beneficios de Sarepta Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$17m
Dec 31 2023	US$2m	US$800k	-US$536m
Sep 30 2023	n/a	n/a	-US$691m
Jun 30 2023	n/a	n/a	-US$908m
Mar 31 2023	n/a	n/a	-US$1b
Dec 31 2022	US$125m	US$740k	-US$703m
Sep 30 2022	n/a	n/a	-US$716m
Jun 30 2022	n/a	n/a	-US$507m
Mar 31 2022	n/a	n/a	-US$357m
Dec 31 2021	US$2m	US$730k	-US$419m
Sep 30 2021	n/a	n/a	-US$486m
Jun 30 2021	n/a	n/a	-US$634m
Mar 31 2021	n/a	n/a	-US$704m
Dec 31 2020	US$1m	US$669k	-US$554m
Sep 30 2020	n/a	n/a	-US$601m
Jun 30 2020	n/a	n/a	-US$530m
Mar 31 2020	n/a	n/a	-US$656m
Dec 31 2019	US$1m	US$650k	-US$715m
Sep 30 2019	n/a	n/a	-US$620m
Jun 30 2019	n/a	n/a	-US$570m
Mar 31 2019	n/a	n/a	-US$403m
Dec 31 2018	US$1m	US$650k	-US$362m
Sep 30 2018	n/a	n/a	-US$245m
Jun 30 2018	n/a	n/a	-US$216m
Mar 31 2018	n/a	n/a	-US$170m
Dec 31 2017	US$57m	US$338k	-US$51m

Compensación vs. Mercado: La compensación total de Doug($USD1.66M) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD5.57M).

Compensación vs. Ingresos: La compensación de Doug ha sido consistente con los resultados de la empresa en el último año.

CEO

Doug Ingram (61 yo)

7yrs

Permanencia

US$1,661,338

Compensación

Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as an Independent Director of Rela...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Douglas Ingram	President	7yrs	US$1.66m	0.41% $ 44.6m
Ian Estepan	Executive VP & CFO	3.5yrs	US$3.71m	0.020% $ 2.2m
Bilal Arif	Executive VP & Chief Technical Operations Officer	1.5yrs	US$3.52m	0.013% $ 1.4m
Louise Rodino-Klapac	Executive VP	3.5yrs	US$3.72m	0.033% $ 3.5m
Ryan Brown	Executive VP	3.5yrs	US$3.58m	0.012% $ 1.3m
Francesca Nolan	Executive Director of Investor Relations and Corporate Communications	no data	sin datos	sin datos
Alison Nasisi	Executive VP & Chief People Officer	2.7yrs	sin datos	sin datos
Diane Berry	Executive VP and Chief of Global Policy & Advocacy Officer	4.8yrs	sin datos	sin datos
Dallan Murray	Executive VP & Chief Customer Officer	3.5yrs	sin datos	0.019% $ 2.1m
Will Tilton	Senior VP	1.4yrs	sin datos	sin datos
Joseph Bratica	Controller & VP	7.3yrs	US$911.89k	sin datos
Mary Jenkins	Senior Manager of Investor Relations	no data	sin datos	sin datos

3.5yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AB3A se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Douglas Ingram	President	7yrs	US$1.66m	0.41% $ 44.6m
M. Behrens	Independent Chairwoman	15.3yrs	US$594.99k	0.20% $ 21.1m
Hans Wigzell	Chairman of Corporate Strategy Board & Independent Non-Employee Director	14yrs	US$546.99k	0.022% $ 2.4m
Richard Barry	Independent Director	9yrs	US$563.65k	3.36% $ 363.0m
Beverly Davidson	Member of Strategic & Scientific Advisory Board	8.8yrs	sin datos	sin datos
Joy Cavagnaro	Member of Scientific Advisory Board	4.6yrs	sin datos	sin datos
Louis Kunkel	Member of Strategic & Scientific Advisory Board	8.8yrs	sin datos	sin datos
Claude Nicaise	Independent Non-Employee Director	9yrs	US$553.34k	0.017% $ 1.9m
Kenneth Fischbeck	Member of Strategic & Scientific Advisory Board	7.3yrs	sin datos	sin datos
Carsten Bonnemann	Member of Scientific Advisory Board	4.5yrs	sin datos	sin datos
Matthew Wood	Member of Strategic & Scientific Advisory Board	7.3yrs	sin datos	sin datos
Annemieke Aartsma-Rus	Member of Scientific Advisory Board	4.6yrs	sin datos	sin datos

8.0yrs

Permanencia media

71yo

Promedio de edad

Junta con experiencia: La junta directiva de AB3A se considera experimentada (7.9 años de antigüedad promedio).

Sarepta Therapeutics Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Sarepta Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Independent Director recently bought €3.7m worth of stock

Insider recently bought €3.4m worth of stock

Insufficient new directors

Insider recently sold €91k worth of stock

Insider recently bought €6.0m worth of stock

Recent updates

Now 23% undervalued

First quarter 2024 earnings released: EPS: US$0.38 (vs US$5.86 loss in 1Q 2023)

Sarepta Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Full year 2023 earnings released: US$5.80 loss per share (vs US$8.03 loss in FY 2022)

Sarepta Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the Elevidys Indication

Sarepta Therapeutics, Inc. Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Sarepta Therapeutics, Inc. Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Independent Director recently bought €3.7m worth of stock

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$2.94 loss in 3Q 2022)

New major risk - Share price stability

Sarepta Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Forecast to breakeven in 2024

Insider recently bought €3.4m worth of stock

Forecast to breakeven in 2024

Second quarter 2023 earnings released: US$0.27 loss per share (vs US$2.65 loss in 2Q 2022)

Sarepta Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Forecast to breakeven in 2024

Sarepta Therapeutics, Inc. Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy

No longer forecast to breakeven

First quarter 2023 earnings released: US$5.86 loss per share (vs US$1.20 loss in 1Q 2022)

Forecast breakeven date moved forward to 2024

Full year 2022 earnings released: US$8.03 loss per share (vs US$5.15 loss in FY 2021)

Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Insufficient new directors

Sarepta Therapeutics Announces That U.S. FDA Has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’S Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy

Forecast to breakeven in 2024

Insider recently sold €91k worth of stock

Third quarter 2022 earnings released: US$2.94 loss per share (vs US$0.60 loss in 3Q 2021)

Hansa Biopharma AB and Partner Sarepta Therapeutics Plan to Initiate A Clinical Study with Imlifidase as A Pre-Treatment to Sarepta's SRP-9001 Gene Therapy in DMD in 2023

Sarepta Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Sarepta Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Sarepta Therapeutics Submits Biologics License Application for Srp-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy

Insider recently bought €6.0m worth of stock

Food and Drug Administration Lifts its Clinical Hold on Sarepta Therapeutics's SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

Insider recently bought €5.0m worth of stock

Second quarter 2022 earnings released: US$2.65 loss per share (vs US$1.02 loss in 2Q 2021)

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

Sarepta Therapeutics, Inc. to Report Q2, 2022 Results on Aug 02, 2022

Sarepta Therapeutics’ Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies

Sarepta Therapeutics, Inc. Provides Update on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. Appoints Michael Chambers and Kathryn Boor to Its Board of Directors

Forecast to breakeven in 2024

First quarter 2022 earnings released: US$1.20 loss per share (vs US$2.11 loss in 1Q 2021)

Sarepta Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Sarepta Therapeutics, Inc. Announces Not Stand for Re-Election of Mary Ann Gray as Board of Director

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Sarepta Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

Sarepta Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Sarepta Therapeutics, Inc. Announces Topline Results from Part 2 of Study SRP-9001-102

Forecast to breakeven in 2024

Insider recently bought €268k worth of stock

President recently bought €1.8m worth of stock

Third quarter 2021 earnings released: US$0.60 loss per share (vs US$2.50 loss in 3Q 2020)

Sarepta Therapeutics, Inc. to Initiate Part B of Momentum Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA

Sarepta Therapeutics, Inc. Raises Product Revenue Guidance for Full Year of 2021

Second quarter 2021 earnings released: US$1.02 loss per share (vs US$1.93 loss in 2Q 2020)

Sarepta Therapeutics, Inc. Announces Positive 12-Week Expression and Safety Results from the First 11 Participants Enrolled in Study SRP-9001-103

First quarter 2021 earnings released: US$2.11 loss per share (vs US$0.23 loss in 1Q 2020)

Sarepta Therapeutics, Inc. Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Sarepta Therapeutics to Share Clinical Update for 30 mg/kg arm of MOMENTUM Study for SRP-5051, Its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy

Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administration

Orsini Specialty Pharmacy Selected By Sarepta Therapeutics As A Limited Distribution Partner For AMONDYS 45 (casimersen)

Full year 2020 earnings released: US$7.11 loss per share (vs US$9.71 loss in FY 2019)

Revenue beats expectations